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S U M M A R Y
Objectives: To explore the clinical characteristics and analyze the pathogens of bacterial meningitis in
children.
Methods: Bacterial meningitis cases occurring from January 2010 through December 2014 at Beijing
Children’s Hospital were reviewed retrospectively. The records of all patients, including data on clinical
features and laboratory information, were obtained and analyzed.
Results: In total, the cases of 507 pediatric patients seen over a 5-year period were analyzed; 220 of these
cases were etiologically conﬁrmed. These patients were classiﬁed into four age groups: 29 days to 1 year
(n = 373, 73.6%), 1–3 years (n = 61, 12.0%), 3–6 years (n = 41, 8.1%), and >6 years (n = 32, 6.3%). The main
pathogens identiﬁed in this study were Streptococcus pneumoniae (n = 73, 33.2%), Escherichia coli (n = 24,
10.9%), Enterococcus (n = 22, 10.0%), and group B Streptococcus (n = 18, 8.2%). All Gram-positive bacteria
were sensitive to vancomycin and linezolid. All Gram-negative bacteria were sensitive to meropenem.
The total non-susceptibility rate of S. pneumoniae to penicillin was 47.6% (20/42). The resistance rates to
ceftriaxone, cefepime, and ceftazidime were 75% (9/12), 55.6% (5/9), and 40% (4/10), respectively.
Conclusions: The main pathogen of bacterial meningitis in this study was S. pneumoniae. The antibiotic
resistance rates among children with bacterial meningitis are of serious concern.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Bacterial meningitis continues to be a major cause of illness and
death among neonates and children throughout the world.1
In population-based studies, the incidence of acute bacterial
meningitis in China ranges from 6.95 to 22.3 cases/100 000
children < 5 years of age.2–4 Neurological sequelae are relatively
common in survivors.5–10 Available studies have shown the
main causal pathogens of bacterial meningitis to be Neisseria* Corresponding authors. Tel.: +86 1059617012.
E-mail addresses: liugang10@hotmail.com (G. Liu), yyh628628@sina.com
(Y.-h. Yang).
1 L.G. and Z.Z. contributed equally to this work
2 Y.Y. and G.L. are co-corresponding authors and contributed equally to this work.
http://dx.doi.org/10.1016/j.ijid.2016.07.010
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).meningitidis, Haemophilus inﬂuenzae type b (Hib), and Streptococcus
pneumoniae.11–15
The incidence of bacterial meningitis has decreased since the
introduction of conjugated vaccines targeting Hib, S. pneumoniae,
and N. meningitidis. The incidence of bacterial meningitis changed
by 31% in the USA during the years 1998–2007, from 2.00 cases
per 100 000 population in 1998–1999 to 1.38 cases per 100 000
population in 2006–2007.14 The epidemiology of meningitis in
Canada has been inﬂuenced dramatically by universal immuniza-
tion programs for Hib, N. meningitidis, and S. pneumoniae.15–17
However, the incidence of this disease and associated deaths
in resource-limited countries continue to grow.18 Accurate
monitoring of the pathogen-speciﬁc estimates of the number of
bacterial meningitis cases is challenging in many countries
because of limited laboratory-based surveillance and the misuseociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Figure 1. Number of bacterial meningitis patients diagnosed per year.
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meningitis were used to describe the distribution of pathogens in
order to provide a baseline for the evaluation of this severe disease
in China.
2. Patients and methods
2.1. Study population
Cases of bacterial meningitis occurring in patients younger than
16 years of age at Beijing Children’s Hospital from January
2010 through December 2014 were reviewed retrospectively. This
tertiary care hospital is a National Children’s Medical Center with
970 beds and treats more than three million outpatients and
70 000 hospitalized patients every year. The records of all patients
with probable or conﬁrmed bacterial meningitis during this 5-year
period were obtained. Demographic data, underlying diseases,
clinical features in the patient history, laboratory ﬁndings,
treatments, and outcomes were reviewed.
2.2. Diagnosis of bacterial meningitis
Any child with a sudden onset of fever (>38.5 8C rectal or
>38.0 8C axillary) and with neck stiffness, altered consciousness,
or other meningeal symptoms was considered a suspected
bacterial meningitis patient. A case that was laboratory-con-
ﬁrmed, with the identiﬁcation of a bacterial pathogen (Hib, S.
pneumoniae, meningococcus, or others) in the cerebrospinal
ﬂuid (CSF) or blood of a child with clinical symptoms consistent
with bacterial meningitis, was considered a ‘proven’ case. A
suspected case with a CSF examination showing at least one of
the following was considered a ‘probable’ case: turbid CSF
appearance, leukocytosis >100  106 cells/l, and leukocytosis of
10–100106 cells/l with either an elevated protein level
(>100 mg/dl) or decreased glucose level (<40 mg/dl). These
criteria are consistent with the World Health Organization
(WHO) case deﬁnition.19
2.3. Sample collection
CSF samples were obtained aseptically from each participant
through lumbar puncture. Up to 1 ml of CSF was collected into a
sterile tube. Samples were sent immediately to the hospital
laboratory for a cell count, Gram staining, and bacterial culture, as
well as to measure glucose and protein levels. Twenty-four hours
after incubation at 35  2 8C in 5% CO2, bacterial isolates were
identiﬁed by colony morphology analysis and growth requirements.
After identiﬁcation, isolates of S. pneumoniae were subsequently
stored at 80 8C until further investigation. An antibiotic suscepti-
bility test for each isolate was performed using the disk diffusion
method or broth microdilution method for the minimum inhibitory
concentration (MIC) values. The results were interpreted according to
the Clinical and Laboratory Standards Institute Performance Stan-
dards for Antimicrobial Susceptibility Testing.20 Staphylococcus
aureus isolates that were resistant to either oxacillin or cefoxitin
were considered methicillin-resistant S. aureus (MRSA). Clinical and
demographic data and the therapeutic history were collected using a
standard case investigation form.
2.4. Bacterial isolates
All S. pneumoniae isolates were identiﬁed based on typical
colony morphology, Gram staining, an optochin sensitivity test
(Oxoid Company, Basingstoke, UK), and an Omni serum assay
(Statens Serum Institute, Copenhagen, Denmark). All isolates were
stored at 80 8C until further study.2.5. Serotyping of S. pneumoniae
The serogroups of S. pneumoniae were tested using the Quellung
reaction with Pneumotest kits, and the serotypes were tested with
factor antisera (Statens Serum Institute). The interpretation of the
serotyping depended on the capsular swelling seen under phase-
contrast microscopy with an oil immersion lens (magniﬁcation,
100), as described in the literature.10
2.6. Ethics statement
This study was reviewed and approved by the Ethics Committee
of Beijing Children’s Hospital Afﬁliated to Capital Medical
University.
2.7. Statistical analysis
Categorical variables were compared using the Chi-square test
or Fisher’s exact test, as appropriate. Continuous variables within
two groups were compared using the independent t-test for
parametric data and the Mann–Whitney U-test for non-parametric
data. p-Values of <0.05 were considered statistically signiﬁcant. All
statistical analyses were conducted using SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA).
3. Results
3.1. Study population
A total of 507 children were included in the study; their median
age was 5 months (range 29 days to 15 years). There were 326
(64.3%) boys and 181 (35.7% ) girls, giving a male to female ratio of
1.8:1. These cases were classiﬁed into four age groups: 29 days to
1 year (n = 373, 73.6%), 1–3 years (n = 61, 12.0%), 3–6 years (n = 41,
8.1%), and >6 years (n = 32, 6.3%). The number of cases diagnosed
each year increased over time, especially in 2014 with 136 patients,
and S. pneumoniae was the predominant pathogen (Figures 1 and
2). A pathogen was identiﬁed in 220 (43.4%) cases, with positive
results in CSF and/or blood.
3.2. Comparison of the pathogen-positive and pathogen-negative
groups
The pathogen-positive group comprised 220 (43.4%) patients
who had at least one pathogenic bacterial strain identiﬁed in either
CSF or blood culture. The pathogen-negative group comprised
287 cases. Patients in the latter group were generally younger than
those in the pathogen-positive group (median age 208 vs. 133 days,
p = 0.003). The two groups of patients did not differ signiﬁcantly in
sex distribution or blood white blood cell (WBC) count. With
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Figure 2. Number of bacterial meningitis cases caused by the main pathogens per
year. (Note: Spn, Streptococcus pneumoniae; Eco, Escherichia coli; En, Enterococcus;
GBS, group B Streptococcus; SA, Staphylococcus aureus.).
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pathogen-positive group were frequently found to have higher
C-reactive protein (70 vs. 40 mg/l, p = 0.005) and procalcitonin
levels (2 vs. 0.75 ng/ml, p = 0.008) than those in the pathogen-
negative group. In terms of CSF indices, patients in the pathogen-
positive group had an apparently lower glucose level (1.7 vs.
2.3 mmol/l, p = 0.019) but higher protein level (1630 vs. 1353 mg/l,
p = 0.0) than those in the pathogen-negative group. There was no
signiﬁcant difference in the CSF WBC count between members of
these two groups, and they had similar complications, sequelae,
and mortality rates. Antibiotic usage before the ﬁrst lumbar
puncture was also similar in the pathogen-positive and pathogen-
negative groups (61.8% vs. 67.3%, p = 0.22) (Table 1).
3.3. Bacterial pathogen composition
The positive rate from the CSF samples was 31% (157/507), and
69 patients also had positive results from blood culture. In
addition, 63 patients had negative results for CSF culture but
positive blood culture results. Positive pathogens were calculated
on the basis of a positive result obtained in the CSF and/or blood. S.
pneumoniae (n = 73, 33.2%), Escherichia coli (n = 24, 10.9%),
Enterococcus (n = 22, 10.0%), and group B Streptococcus (GBS)
(n = 18, 8.2%) were the most frequently detected pathogens in this
study (Figure 2). In addition, there were nine instances of S. aureus
(4.1%), nine of Pseudomonas aeruginosa (4.1%), and eight of
Salmonella (3.6%). There were only ﬁve cases of H. inﬂuenzae
and one of N. meningitidis during the 5-year period. The number ofTable 1
Comparison of pathogen-positive and positive-negative groupsa
Total
N=507
Pa
n=
Age(days) 151(74–398) 20
Male(%) 64.3% 60
Blood WBC count (109/l) 11.8(7.8–16.9) 11
Blood CRP (mg/l) 57(8–135) 70
PCT (ng/ml) 1(0.3–10) 2(
CSF WBC count (106/l) 390(110–1600) 39
CSF glucose (mmol/L) 2.2(0.88–2.96) 1.7
CSF protein (mg/L) 1469.5(849.3–2361.3) 16
Complications (%) 54.0% 57
Sequela (%) 29.0% 29
Mortality (%) 0.8% 1.4
Antibiotic use before lumbar puncture (%) 64.9% 61
WBC, white blood cell;CRP, C-reactive protein; PCT, procalcitonin; CSF, cerebrospinal ﬂ
a Results are reported as the median (interquartile range), or as the percentage.cases diagnosed each year increased over time, and S. pneumoniae
was the predominant pathogen with eight to 22 cases per year. In
terms of the pathogen composition by age group, it was notable
that S. pneumoniae was predominant in all age groups (from 21.3%
to 64.0%), except the <1 year age group (Figure 3).
In the group of patients aged 29 days to 1 year, E. coli and GBS
were the second and third most prevalent pathogens, respectively.
Of the patients with E. coli, 91.7% (22/24) were less than 1 year old.
Patients with a GBS infection were all infants between 1 and
4 months old.
3.4. Antimicrobial susceptibility testing
Penicillin susceptibility results were available for 42
S. pneumoniae isolates. The total non-susceptibility (intermediate
and resistant) rate to penicillin was 47.6% (20/42), as deﬁned by the
parenteral meningitis breakpoint (susceptible 0.06 mg/l, resis-
tant 0.12 mg/l). The incidence of S. pneumoniae showed an
increasing trend each year (from eight to 22 cases), with steady
non-susceptibility rates (33.3–57.1%) (Figure 4). The susceptibility
of the 42 S. pneumoniae isolates to antibiotics is shown in
Figure 5. The non-susceptibility rates to ceftriaxone, cefotaxime,
and cefepime were 25%, 46.9%, and 51.9%, respectively. There were
no S. pneumoniae isolates that were resistant to vancomycin or
linezolid (Table 2).
There were 24 isolates of E. coli. All of the isolates were resistant
to ampicillin and cefuroxime. The resistance rates to ceftriaxone,
cefepime, and ceftazidime were 75% (9/12), 55.6% (5/9), and 40%
(4/10), respectively. There were no E. coli isolates that were
resistant to carbapenems (meropenem, ertapenem, and imipe-
nem), amikacin, cefoperazone, or sulbactam. There were 18 isolates
of GBS. There were no GBS isolates that were resistant to
vancomycin, linezolid, penicillin G, ceftriaxone, or cefepime. There
were nine isolates of S. aureus, including three isolates of MRSA and
four isolates of methicillin-sensitive S. aureus (MSSA). The
resistance rates to penicillin G, oxacillin, and tetracycline were
85.7% (6/7), 33.3% (2/6), and 33.3% (2/6), respectively. There were
no S. aureus isolates that were resistant to vancomycin, teicoplanin,
linezolid, or levoﬂoxacin (Table 2).
3.5. S. pneumoniae serotype distribution and vaccine coverage
A total of ﬁve serotypes were identiﬁed among the 12
S. pneumoniae isolates. There were four isolates of serotype 19F,
three isolates of 23F, two isolate each of 19A and 14, and one isolate
of 6A . The total coverage rates of pneumococcal conjugate
vaccines PCV7, PCV10, and PCV13 were 75.0% (9/12), 75.0% (9/12),
and 100% (12/12), respectively.thogen-positive
220
Pathogen-negative
n = 287
Chi-square p-Value
8(86–527) 133 (70–308) 0.003
.4% 67.4% 2.67 0.113
.2(7.1–17.0) 12.4 (8.6–16.8) 0.1
(15–160) 40 (8–115) 0.005
0.38–11) 0.75 (0.2–5.78) 0.008
5(95–1633) 390 (120–1600) 0.521
(0.4–2.7) 2.4(1.4–3.1) 0.019
30(970–2600) 1353 (807–2155) 0
.3% 51.4% 1.746 0.206
.8% 28.4% 0.117 0.767
% 0.4% 0.322
.8% 67.3% 1.634 0.22
uid.
Figure 3. The distribution of different pathogens by age group. (Note: Spn, Streptococcus pneumoniae; Eco, Escherichia coli; En, Enterococcus; GBS, group B Streptococcus; SA,
Staphylococcus aureus; Pae, Pseudomonas aeruginosa.).
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Since the introduction of conjugated vaccines targeting Hib,
S. pneumoniae, and N. meningitidis, there has been a decreasing
incidence of bacterial meningitis in infants and children in the USA
and Canada. However, the situation in China is markedly different.
A recent study reported that for children <5 years of age, the
estimated incidence was 6.95–22.3 cases/100 000 children,4 which
was similar to that found previously in other studies performed in
China (from 12.4 to 19.2 cases/100 000 children2,3).
In the present study covering the period January 2010 to
December 2014, there were 507 cases of suspected bacterial
meningitis in the hospital, and the number of cases enrolled per
year increased over this 5-year period. Furthermore, the pathogen
was identiﬁed and conﬁrmed in 220 patients by blood and/or CSF
culture, in accordance with the WHO criteria.
Of note, the proportion of cases caused by S. pneumoniae (33.2%)
was relatively high (ranging from 21.3% to 64.0% across age
groups). Similar to other countries, low incidences of H. inﬂuenzae
(ﬁve cases) and Neisseria infection (one case) were found during
the 5-year period. The factors related to the low positive rates for
these two pathogens of bacterial meningitis are complex. One key
contributing factor is that a meningococcal vaccine has been part of
the National Immunization Program (NIP) since the 1980s; theFigure 4. Number of Streptococcus pneumoniae isolates with non-susceptibility to
penicillin.coverage of group A meningococcal polysaccharide reported in
2012 was 91.22%.21 The Hib vaccine has been in use since the
1990s with a coverage of 50.9%,22 even though it has not been
included in the NIP. The other key factor is the high rate of
antimicrobial drug use in clinical practice in China. Of the bacterial
meningitis patients in the present study, 63.9% had used
antibiotics before clinical specimens were collected. This ﬁnding
is similar to that of a previous study in China.4 Antibiotic abuse is
an increasing threat in China. According to a survey performed at
Beijing Children’s Hospital, more than 98% of patients in the
outpatient department who were diagnosed with the common
cold were given antibiotics by physicians. More than one-third of
the patients had been taking antibiotics before coming to the
hospital.23
The World Health Organization has sounded the alarm on the
abuse of antibiotics in China. The use of antibiotics in this country
is very high. Over the past decade, more than half of outpatients in
China have been prescribed antibiotics—far above the level
recommended by the WHO (less than 30%). Antibiotic treatment
reduces the positive rate from CSF samples in bacterial meningitis
cases. Dalton and Allison showed that antibiotic treatment reduced
the number of positive cultures recovered from the CSF by
approximately 30%.24,25
S. pneumoniae infection is a serious but vaccine-preventable
cause of meningitis. The S. pneumoniae vaccine was introduced in
China at the end of 2008 and was stopped at the end of 2014; it has
not been introduced into the NIP.26 The immunization rates with
this vaccine were low, primarily because of its high price
(860 RMB/dose, approximately US$ 138.5/dose). One study
performed in 2014 in Shanghai showed a PCV vaccine coverage
of 11.4% from 28 141 abstracted pediatric records.22
In the present study, a total of ﬁve serotypes were identiﬁed
among 12 S. pneumoniae isolates. There were four isolates of
serotype 19F, three isolates of 23F, two isolates each of 19A and 14,
and one isolate of 6A. The total coverage rates of PCV7, PCV10, and
PCV13 were 75.0%, 75.0%, and 100%, respectively. Many studies
have shown that certain S. pneumoniae serotypes, especially
vaccine serotypes, are related to more severe invasive pneumo-
coccal infections. Serotypes 19F and 19A were found to be the most
common serotypes associated with severe S. pneumoniae
100.0%
64.5%
58.1%
51.9%
47.6% 46.9%
25.0%
0.0% 0.0% 0.0% 0.0%
45.2%
38.7% 37.0%
45.2%
12.5%
6.3%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
NS% R%
Figure 5. Susceptibility of the Streptococcus pneumoniae isolates to antibiotics. (Note: NS, non-susceptible; R, real resistance; SMZ, sulfamethoxazole.) .
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recent study from the USA showed that serotype 19A was the
major multidrug-resistant S. pneumoniae (MDRSP) (38.5%).29
Another study in China including 171 S. pneumoniae isolates from
invasive S. pneumoniae diseases in children, showed that the most
common serotypes were 19F (19.9%), 14 (19.3%), and 19A (18.1%).
Thus, the incidence of invasive S. pneumoniae infections, especially
pneumococcal meningitis, may decrease signiﬁcantly following
the complete introduction of PCV (especially PCV13) in China.
A high level of antibiotic resistance in S. pneumoniae isolates
was found in the present study. The penicillin non-susceptibility
rate was 47.6%, which is signiﬁcantly higher than rates reported in
developed countries (24.4% in Europe,30 38.9–42.7% in the U.S.,31
and 3.9% in Canada15), but lower than the rate reported in a study
from Shanghai, China34 (70%). The non-susceptibility rates toTable 2
Real resistance of the main pathogenic bacterial meningitis strains (n/N)
Antibiotics Spn Eco GBS SA
Penicillin G 19/42  0/14 6/7
Ampicillin 0/4 8/9  
Amoxicillin–clavulanic acid 0/1 1/10  
Piperacillin  1/10  
Oxacillin 0/2   2/6
Cefoxitin  0/9  
Cefuroxime  9/11  
Ceftazidime  4/10  
Cefoperazone–sulbactam  0/12  
Cefotaxime 4/32   
Ceftriaxone 1/16 9/12 0/10 1/1
Cefepime 10/27 5/9 0/9 
Vancomycin 0/56  0/14 0/7
Linezolid 0/29   0/7
Teicoplanin    0/4
Ciproﬂoxacin  5/9  0/7
Levoﬂoxacin 0/14   0/6
Amikacin  0/9  
Meropenem 14/31 0/15  
Ertapenem 0/3 0/3  
Imipenem  0/11  
Gentamicin  4/9  
Chloramphenicol 0/28   1/1
Rifampicin 0/3   0/7
Tetracycline 4/6   2/6
Sulfamethoxazole 12/31 8/9  1/6
Spn, Streptococcus pneumoniae; Eco, Escherichia coli; GBS, group B Streptococcus;
SA, Staphylococcus aureus.penicillin are increasing, and this ﬁnding coincides with global
trends.32,33 No S. pneumoniae isolates were found to be resistant to
vancomycin or linezolid, which is consistent with the ﬁndings of
another study.34
This study has several limitations. It was a hospital-based
retrospective review. Because some patients only had positive
culture results at other hospitals before admission, the resistance
data for the different antibiotics are incomplete. For the same
reason, only 12 S. pneumoniae isolates were available for
serotyping. Thus, this study might not represent overall epidemic
trends in China. Future longitudinal, prospective and multicenter
surveillance for pathogens of bacterial meningitis should be
conducted. Moreover, the serotype distribution, antimicrobial
susceptibility, and molecular epidemiology of S. pneumoniae are
required.
In conclusion, the main pathogen of bacterial meningitis in this
study was S. pneumoniae. The antibiotic resistance rates among
children with bacterial meningitis are of serious concern.
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